The stock's rise snapped a three-day losing streak.

McKesson Corp. engages in providing healthcare services. It operates through the following segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Barclays analyst Stephanie Davis maintained a Buy rating on McKesson (MCK – Research Report) today and set a price target of $616.00. The company’s shares closed yesterday at $514.75.

It indicates an expandable section or menu, or sometimes previous / next navigation options. PNG is a popular graphic file format, perhaps second only to JPG today. It has a few advantages over ...

Shares of McKesson (MCK) are oversold. They are also at a potential support level. Stocks that are oversold and at support tend to rally. The best traders traders focus on key price levels and ...

Deutsche Bank analyst George Hill maintained a Buy rating on McKesson (MCK – Research Report) today and set a price target of $579.00. George Hill has given his Buy rating due to a combination ...

McKesson (MCK) closed at $488.78 in the latest trading session, marking a -1.95% move from the prior day. This change lagged the S&P 500's daily gain of 0.01%. Elsewhere, the Dow saw an upswing of ...

(Bloomberg) -- Several publicly traded drug distributors are vying to buy Florida Cancer Specialists & Research Institute, a privately held operator of oncology clinics, people familiar with the ...

San Francisco, CA-based McKesson Corporation is a health care services and information technology company. McKesson operates through two segments: MCK boasts a Value Style Score of A and VGM Score ...